Medical-products manufacturer Invacare Corp. is two-thirds of the way to getting Food and Drug Administration permission to resume full-scale production at a key U.S. facility. But with that wheelchair-producing plant still hobbled by a 2012 FDA consent decree, the company reported a net loss of $18 million in its first quarter compared to a net loss of $5.7 million in the same period last year.
The loss came as net sales for the quarter fell 6.7% to $309.1 million from $331.4 million in the same period last year. The company in late 2012 entered into a FDA consent decree to limit production of custom power and manual wheelchairs, wheelchair components and wheelchair subassemblies at its Taylor Street plant in its headquarters city of Elyria, Ohio, after what were termed “inspectional observations” by the FDA. Following the decree, it laid off 40% of its hourly workers at the plant.